CALCISCON was founded in 2013 as a result of a breakthrough research in renal medicine by Dr. Andreas Pasch.
He investigated why the blood vessels of kidney patients calcify rapidly. This work led to the development of the T50, the first functional test for the assessment of Calcification Propensity. T50 identifies patients with high cardiovascular risk, and opens the possibility to slow down disease progression.

Calciscon offers its CE-marked T50 blood test to patients through accredited medical laboratories.

The basic underlying principle of T50 reflects a generalized phenomenon in the entire body, and is thus potentially applicable to multiple medical conditions. Measurement in blood is linked to cardiovascular risk. Measurement in urine may be linked to kidney stone formation. Measurement in amniotic fluid correlates with early rupture of the membranes in pregnancy. T50 may also be a driver of accelerated aging and disease progression of dementia.

Calciscon offers a measurement service for testing Calcification Propensity in blood, urine or other sample types, through its laboratories located in Nidau (Switzerland).